| abstract |
The present invention relates to a pharmaceutical composition containing a SIRT2 inhibitor and, more specifically, to: a pharmaceutical composition for preventing or treating renal inflammatory diseases, which are caused by sepsis, by controlling inflammation-inducing factors by sepsis through the regulation of SIRT2 gene expression so as to reduce renal inflammation, thereby preventing a kidney injury; and a pharmaceutical composition for preventing or treating cancer, having an effect of increasing anticancer efficacy while reducing nephrotoxicity, which is a side effect of cisplatin, when administered together with cisplatin. |